Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Raymond James Financial

Investment analysts at Raymond James Financial started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report issued on Friday,Benzinga reports. The firm set an “outperform” rating and a $56.00 price target on the stock. Raymond James Financial’s target price suggests a potential upside of 94.31% from the stock’s current price.

A number of other brokerages have also recently commented on FTH. Citigroup started coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings began coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.89.

Sensei Biotherapeutics Stock Performance

NASDAQ FTH opened at $28.82 on Friday. The company has a market cap of $38.62 million, a PE ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics has a 52-week low of $7.10 and a 52-week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, equities analysts predict that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Transactions at Sensei Biotherapeutics

In related news, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were purchased at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the acquisition, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 49,494 shares of company stock worth $1,188,822 over the last quarter. 7.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the first quarter valued at $22,758,000. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.